Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | AOC1 | P19801 | 7/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529877 | 1.00 | LOXL2 (0.38) | LOXL2AOC1AOC3RXRAGRIN1 | |
| SCHEMBL29530331 | 0.83 | LOXL2 (0.44) | LOXL2AOC1AOC3KCNH2NOS3 | |
| SCHEMBL25321760 | 0.83 | LOXL2 (0.44) | LOXL2AOC1AOC3KCNH2NOS3 | |
| SCHEMBL29530232 | 0.79 | HTT (0.37) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL29102328 | 0.79 | TGFBR1 (0.35) | AOC1AOC3RXRAGRIN1GRIN2B | |
| SCHEMBL25323757 | 0.79 | HTT (0.37) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL25319886 | 0.79 | MGAT2 (0.37) | LOXL2AOC1AOC3NOS3NOS1 | |
| SCHEMBL25320177 | 0.75 | AOC3 (0.40) | LOXL2AOC1AOC3NOS3NOS1 | |
| SCHEMBL29530430 | 0.75 | AOC3 (0.40) | LOXL2AOC1AOC3NOS3NOS1 | |
| SCHEMBL25318095 | 0.74 | AOC3 (0.44) | LOXL2AOC1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | LOXL2 1565/4885AOC1 1586/4885AOC3 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.